NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗體藥物複合體 (ADC) 市場 - 預測,COVID-19的影響、復甦模式分析,主要企業的簡介:2021年∼2031年

Antibody Drug Conjugates Market Report 2021-2031: Forecasts by Technology, Payload Type, Target Antigen, Drug Type, Application, Linker Type, COVID-19 Impact & Recovery Pattern Analysis, Profiles of Leading Companies, Region & Country

出版商 Visiongain Ltd 商品編碼 983571
出版日期 內容資訊 英文 498 Pages
商品交期: 最快1-2個工作天內
價格
抗體藥物複合體 (ADC) 市場 - 預測,COVID-19的影響、復甦模式分析,主要企業的簡介:2021年∼2031年 Antibody Drug Conjugates Market Report 2021-2031: Forecasts by Technology, Payload Type, Target Antigen, Drug Type, Application, Linker Type, COVID-19 Impact & Recovery Pattern Analysis, Profiles of Leading Companies, Region & Country
出版日期: 2020年11月03日內容資訊: 英文 498 Pages
簡介

本報告提供全球抗體藥物複合體 (ADC) 市場相關調查分析,現狀,市場動態,市場預測,主要企業等相關的系統性資訊。

目錄

第1章 報告概要

第2章 摘要整理

第3章 抗體藥物複合體 (ADC) 技術的背景

  • 概要
  • ADC的作用機制
  • ADC的零組件
  • ADC的功能
  • 抗體藥物複合體 (ADC) 技術
  • 單株抗體的種類

第4章 ADC市場現狀

  • FDA核準的抗體藥物複合體 (ADC)
  • 全球市場的臨床研究用的ADC
  • 對抗體藥物複合體 (ADC) 的創新的連接試劑技術
  • 抗體藥物複合體 (ADC) 市場SWOT分析
  • 波特的五力分析

第5章 促進市場成長的要素/阻礙因素

  • 市場促進因素
  • 市場成長的阻礙因素
  • 世界市場機會

第6章 全球市場預測 (COVID的影響復甦分析)

  • 全球抗體藥物複合體 (ADC) 市場價值
  • 抗體藥物複合體 (ADC) 市場主要地區
  • 全球ADC市場分析:各技術
  • 全球ADC市場分析:各酬載類型
  • 全球ADC市場分析:各目標抗原
  • 全球ADC市場分析:各藥物類型
  • 全球ADC市場分析:各連接試劑類型
  • 抗體藥物複合體 (ADC) 市場需求促進用途

第7章 北美市場預測 (COVID的影響復甦分析)

第8章 歐洲市場預測 (COVID的影響復甦分析)

第9章 亞太地區市場預測 (COVID的影響復甦分析)

第10章 南美、中東、非洲市場預測 (COVID的影響復甦分析)

第11章 主要企業簡介

  • 概要
  • AbbVie Inc. Company
  • Astellas Pharmaceuticals Company
  • Bayer Pharmaceuticals Company
  • Celldex Therapeutics Company
  • Genentech Biotechnology Company
  • ImmunoGen Biotechnology Company
  • Immunomedics Inc. Company
  • Lonza Group AG Company
  • Mersana Therapeutics Inc. Company
  • Takeda Pharmaceuticals Company Ltd.
  • Pfizer Inc Company
  • F. Hoffmann-La Roche Ltd Company
  • Lantheus Holdings Company
  • Seattle Genetics Company
  • Merck Group Chemicals Company

第12章 抗體藥物複合體 (ADC) 產品的開發平台分析

第13章 結論與建議

目錄
Product Code: PHA0556

Title:
Antibody Drug Conjugates Market Report 2021-2031
Forecasts by Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), by Payload Type (MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), by Target Antigen (CD30, HER2, CD22, CD33), by Drug Type (Adcetris, Kadcyla, Other Drugs), by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Application), by Linker Type (VC, VA, SMCC, Hydrazone, Other Linker Type). PLUS COVID-19 Impact Analysis and Recovery Pattern.

Analysis (V-shaped, W-shaped, U-shaped, L-shaped) AND Profiles of Leading Companies, Region and Country

Visiongain has estimated that the total market for Antibody Drug Conjugates would be around $xx billion in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Shouldn't you be part of this market?

Antibody drug conjugate (ADC) technology continues to evolve as a widely successful drug targeting technology for the treatment of cancer. Advances in targeting antibodies, potent payloads and drug-linker technologies that facilitate improved ADC stability, potency and targeting efficiency led to the development of ten commercially viable ADCs. Shouldn't you be part of this innovative market?

Antibody Drug Conjugates Market - Our new market research study shows trends, developments, progress in R&D and forecast revenue till 2031. The study offers YOU an in-depth assessment of competitors journeys within the market and its segments.

This report tell you how to stay ahead

Almost 600 tables and graphs are included in our just 500-page report. Read about the most lucrative industries and the future prospects on the market. Our new study allows you to evaluate forecast sales worldwide and regional. See financial results, trends, opportunities and forecasts of revenue. In this growing Antibody Drug Conjugates market a lot of opportunity remains. See how opportunities can be taken advantage of.

What are the key factors to reshaping the growth of the Antibody Drug Conjugates market? You must read this new report immediately. This exclusive report by Visiongain shows you potential revenue opportunity pool until 2031 for the assessment of data, trends, opportunities and business outlooks.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

Visiongain has estimated that the total market for Antibody Drug Conjugates would be around $xx billion in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Shouldn't you be part of this market?

Antibody drug conjugate (ADC) technology continues to evolve as a widely successful drug targeting technology for the treatment of cancer. Advances in targeting antibodies, potent payloads and drug-linker technologies that facilitate improved ADC stability, potency and targeting efficiency led to the development of ten commercially viable ADCs. Shouldn't you be part of this innovative market?

Antibody Drug Conjugates Market - Our new market research study shows trends, developments, progress in R&D and forecast revenue till 2031. The study offers YOU an in-depth assessment of competitors journeys within the market and its segments.

This report tell you how to stay ahead

Almost 600 tables and graphs are included in our just 500-page report. Read about the most lucrative industries and the future prospects on the market. Our new study allows you to evaluate forecast sales worldwide and regional. See financial results, trends, opportunities and forecasts of revenue. In this growing Antibody Drug Conjugates market a lot of opportunity remains. See how opportunities can be taken advantage of.

What are the key factors to reshaping the growth of the Antibody Drug Conjugates market? You must read this new report immediately. This exclusive report by Visiongain shows you potential revenue opportunity pool until 2031 for the assessment of data, trends, opportunities and business outlooks.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

How Increased Research on ADC Development Will Help the Market to Grow?

ADC Industry Involves a Specialization Business Model - be part of its success.

Will Innovation in ADCs Disrupt the Market in Future?

  • Use of known or approved antibodies and cytotoxins in ADCs means potentially streamlined reviews and briefer development cycles.
  • Technological advances, including stable linker technologies, have provided the impetus to develop more targeted and efficacious ADCs.
  • Development of more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs have an improved safety/efficacy profile.
  • Increasing incidence of cancer is also contributing to the development of ADCs.

Is Complexity of ADCs hindering its Growth?

Manufacturing an ADC is a complex process. It requires a small molecule, an antibody, chemical linking chemistry and different amino acid conjugation. Antibody drug conjugates exhibit a more complex and heterogeneous structure than the parent monoclonal antibody. This complexity and heterogeneity present a significant challenge for generic manufacturers to copy the ADCs; thus, the complexity of ADCs preserves companies' investment longer.

Forecasts to 2031 and other analyses reveal the commercial prospects of Antibody Drug Conjugates Market

  • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the Antibody Drug Conjugates market and submarkets

Global Antibody Drug Conjugates Market by Technology

  • Cleavable Linkers
  • Non-Cleavable Linkers
  • Other Technology

Global Antibody Drug Conjugates Market by Payload Type

  • MMAE
  • DM4
  • Camptothecin
  • DM1
  • MMAF
  • Other Payload Type

Global Antibody Drug Conjugates Market by Target Antigen

  • CD30
  • HER2
  • CD22
  • CD33

Global Antibody Drug Conjugates Market by Drug Type

  • Adcetris
  • Kadcyla
  • Other Drugs

Global Antibody Drug Conjugates Market by Application

  • Blood Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Lung Cancer
  • Brain Tumor
  • Other Application

Global Antibody Drug Conjugates Market by Linker Type

  • VC
  • VA
  • SMCC
  • Hydrazone
  • Other Linker Type

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:

North America Antibody Drug Conjugates Market Outlook

  • U.S. Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Canada Antibody Drug Conjugates Market Forecast & COVID Impact Analysis

Europe Antibody Drug Conjugates Market Outlook

  • Germany Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • France Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • United Kingdom Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Italy Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Russia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Rest of Europe Market Forecast & COVID Impact Analysis

Asia Pacific Antibody Drug Conjugates Market Outlook

  • China Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Japan Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • India Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Australia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • South Korea Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Rest of Asia Pacific Market Forecast & COVID Impact Analysis

Latin America Antibody Drug Conjugates Market Outlook Market Forecast & COVID Impact Analysis

  • Brazil Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Mexico Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Rest of Latin America Market Forecast & COVID Impact Analysis

Middle East and Africa Antibody Drug Conjugates Market Outlook

  • Saudi Arabia Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • South Africa Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • UAE Antibody Drug Conjugates Market Forecast & COVID Impact Analysis
  • Rest of Middle East and Africa

The report also includes profiles and for some of the leading companies in the Antibody Drug Conjugates Market, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

  • AbbVie Inc.
  • Astellas Pharma Inc
  • Bayer Pharmaceuticals
  • Celldex Therapeutics, Inc.
  • Genentech Biotechnology
  • ImmunoGen Biotechnology
  • Immunomedics Inc
  • Lonza Group AG (Lonza)
  • Mersana Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • Roche Holding AG (Roche)
  • Pfizer Inc. (Pfizer)
  • Lantheus Holdings, Inc.
  • Seattle Genetics, Inc.
  • Merck KGaA

Overall world revenue for Antibody Drug Conjugates Market will surpass $xx billion in 2020, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

Key Questions Answered in the report:

  • What are the best investment options for venturing into new product and service lines?
  • What value proposals should businesses aim at while providing new funding for research and development?
  • Which regulations will be most useful for stakeholders to enhance their supply chain network?
  • Which regions could see demand ripening in certain segments in the near future?
  • What are some of the best cost optimization strategies with vendors that some well-trained players have been successful with?
  • What are the key perspectives that C-suite is leveraging to move businesses to a new growth trajectory?
  • Which government regulations could call into question the status of key regional markets?
  • How will the emerging political and economic scenario affect opportunities in key areas of growth?
  • What are some of the value-added opportunities in different segments?
  • What will be the barriers to entry for new players on the market?

How the Antibody Drug Conjugates Market report helps you?

In summary, our 490+ page report provides you with the following knowledge:

  • Revenue forecasts to 2031 for Antibody Drug Conjugates Market, with forecasts for Technology, Linker Type, Drug Type, Payload Type, Application each forecasted at a global and regional level- discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2031 for 5 regional and 20 key national markets - See forecasts for the Antibody Drug Conjugates market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Russia, Germany, France, UK, Italy, China, India, Japan, Korea and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market- including company profiles for 15 of the major companies involved in the Antibody Drug Conjugates Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Antibody Drug Conjugates Market and leading companies. You will find data, trends and predictions.

Buy our report today Antibody Drug Conjugates Market Report 2021-2031: Forecasts by Technology (Cleavable Linkers, Non-Cleavable Linkers, Other Technology), by Payload Type (MMAE, DM4, Camptothecin, DM1, MMAF, Other Payload Type), by Target Antigen (CD30, HER2, CD22, CD33), by Drug Type (Adcetris, Kadcyla, Other Drugs), by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Application), by Linker Type (VC, VA, SMCC, Hydrazone, Other Linker Type). PLUS COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped) AND Profiles of Leading Companies, Region and Country. Avoid missing out by staying informed - order our report now.

Table of Contents

1 Report Overview

  • 1.1 Global Antibody Drug Conjugate Market Overview
  • 1.2 Visiongain Study Goals and Objectives
  • 1.3 Why it is Important to Study This Market?
  • 1.4 What is the Scope of this Report?
  • 1.5 Market Definitions
    • 1.5.1 Antibody
    • 1.5.2 Antigen
    • 1.5.3 Cytotoxicity
    • 1.5.4 Endocytosis
    • 1.5.5 Immune system
    • 1.5.6 Hybridoma Technology
    • 1.5.7 Antibody drug conjugates (ADCs)
  • 1.6 Why You Should Read This Report
  • 1.7 How This Report Delivers
  • 1.8 Key Questions Answered by This Analytical Report Include:
  • 1.9 Who is This Report for?
  • 1.10 Methodology
    • 1.10.1 Primary Research
    • 1.10.2 Secondary Research
  • 1.11 Market Segmentation
  • 1.12 Frequently Asked Questions (FAQ)
  • 1.13 Associated Visiongain Reports

2 Executive Summary

  • 2.1 What are the Advantages of ADCs

3 Antibody Drug Conjugate Technology Background

  • 3.1 Overview
  • 3.2 The Action Mechanism of ADC
  • 3.3 Components of ADCs
  • 3.4 How ADCs Work?
  • 3.5 Antibody Drug Conjugation Technologies
    • 3.5.1 How Good are Cysteine Conjugation?
    • 3.5.2 Conjugation Methods Overview
    • 3.5.3 Cysteine-Based Conjugation
    • 3.5.4 Lysine-Based Conjugation
    • 3.5.5 Site-Specific Conjugation
  • 3.6 Types of Monoclonal Antibodies

4 What is the Current Status of ADCs Market?

  • 4.1 FDA Approved Antibody Drug Conjugates
  • 4.2 ADCs for Clinical Research in the Global Market
  • 4.3 Innovative Linker Technology for Antibody Drug Conjugates (ADCs)
  • 4.4 SWOT Analysis of Antibody Drug Conjugates Market
    • 4.4.1 Strengths of ADC Market
      • 4.4.1.1 The unique targeting capabilities and promising clinical trial results
      • 4.4.1.2 Advances in targeting antibodies, potent payloads and drug-linker technologies
      • 4.4.1.3 The growing number of cancer patients and increasing demand for biologics for the treatment
    • 4.4.2 Weaknesses of ADC Market
      • 4.4.2.1 dose-limiting toxicities such as liver toxicity or neutropenia
      • 4.4.2.2 disulfide-based linkers suffer from premature loss of payload cargo
      • 4.4.2.3 leading to less drug delivered to the tumor and more toxicity
    • 4.4.3 Opportunities in the ADC Market
      • 4.4.3.1 an innovative class of drugs that are mainly developed by conjugating already
      • 4.4.3.2 have the potential to replace conventional treatment options
      • 4.4.3.3 Most pharmaceutical companies are investing in the ADC industry
    • 4.4.4 Threats in the ADC Market
      • 4.4.4.1 The development of any drug is no simple matter, and it is even more complex for ADCs
      • 4.4.4.2 ADC mechanistic pathway consists of a complicated sequence of events
      • 4.4.4.3 Pathway complexity is the main reason so many previous attempts have been unsuccessful
  • 4.5 Porter's Five Forces Analysis
    • 4.5.1 Threat of New Entrants (High)
    • 4.5.2 Rivalry Among the Existing Players (Low)
    • 4.5.3 Bargaining Power of Suppliers (High)
    • 4.5.4 Threats from Substitute Products (Moderate to High)
    • 4.5.5 Bargaining Power of Buyers (Low)

5 Which Factors Are Driving or Restraining the Growth of the Market?

  • 5.1 Which are Market Driving Forces?
    • 5.1.1 Is Patent Expiration a Master Key to Enter Global Market?
    • 5.1.2 Targeted Nature of ADCs is Promising
    • 5.1.3 How Increased Research on ADC Development Will Help the Market to Grow?
    • 5.1.4 How Technological Advancements Are Driving Growth?
    • 5.1.5 ADC Industry Involves a Specialization Business Model
    • 5.1.6 Will Innovation in ADCs Disrupt the Market in Future?
    • 5.1.7 Other Factors Boosting the Market Growth
  • 5.2 Which Barriers Are Restraining the Market Growth?
    • 5.2.1 Is Complexity of ADCs hindering its Growth?
    • 5.2.2 Which are the Regulatory Issues Associated with ADC Products?
    • 5.2.3 Regulatory Exclusivity
    • 5.2.4 Which Challenges Companies have to Face in the Global Market?
  • 5.3 What are the Opportunities in the Global Market?
    • 5.3.1 Growth in Number of Cancer Patients in the World
    • 5.3.2 Increasing Cost of Cancer Treatment

6 Global Market Outlook (COVID Impact Recovery Analysis)

  • 6.1 How Much Worth is the Global Antibody Drug Conjugate Market?
  • 6.2 Which Region is Leading the Antibody Drug Conjugate Market?
  • 6.3 Global ADC Market Analysis by Technology
    • 6.3.1 Is Cleavable Linkers Really in Demand?
    • 6.3.2 Type of Linkers
  • 6.4 Global ADC Market Analysis by Payload Type
    • 6.4.1 Why MMAE Payload is Gaining More Traction than Others?
    • 6.4.2 Types of Payloads (Cytotoxic Agents)
    • 6.4.3 MMAE
    • 6.4.4 DM4
    • 6.4.5 Camptothecin
    • 6.4.6 DM1
    • 6.4.7 MMAF
  • 6.5 Global ADC Market Analysis by Target Antigen
    • 6.5.1 CD19
    • 6.5.2 CD20
    • 6.5.3 CD22
    • 6.5.4 CD25
    • 6.5.5 CD30
    • 6.5.6 CD33
    • 6.5.7 CD40
    • 6.5.8 CD56
    • 6.5.9 CD74
    • 6.5.10 CD79a and CD79b
    • 6.5.11 CD138 (Syndecan-1)
    • 6.5.12 CEACAM (Carcinoembryonic Antigen-Related Cell Adhesion Molecule)
    • 6.5.13 EGFR (Epidermal Growth Factor Receptor/ERBB1)
    • 6.5.14 EGP-1 (Epithelial Glycoprotein-1 Antigen)
    • 6.5.15 GPNMB
    • 6.5.16 LIV-1
    • 6.5.17 Mesothelin
    • 6.5.18 Nectin-4
    • 6.5.19 Prostate-Specific Membrane Antigen (PSMA)
    • 6.5.20 SLITRK6
    • 6.5.21 VEGF (Vascular Endothelial Growth Factor)
    • 6.5.22 HER2 Targeting ADCs
  • 6.6 Global ADC Market Analysis by Drug Type
    • 6.6.1 Adcetris
    • 6.6.2 Kadcyla
  • 6.7 Global Antibody Drug Conjugates Market Analysis by Linker Type
    • 6.7.1 Valine-Citrulline (VC)
    • 6.7.2 Sulfo-SPDB
    • 6.7.3 SMCC
    • 6.7.4 VA
    • 6.7.5 Hydrazone
  • 6.8 Which Application is Driving More Demand for Antibody Drug Conjugate Market?
    • 6.8.1 ADC Application Overview
    • 6.8.2 Breast Cancer
    • 6.8.3 Lymphoma
    • 6.8.4 Other Types of Cancer

7 North America Market Outlook (COVID Impact Recovery Analysis)

  • 7.1 How North America is Dominating the Global Antibody Drug Conjugate Market?
  • 7.2 North America Antibody Drug Conjugates Market by Country
  • 7.3 US Antibody Drug Conjugate Market Outlook
  • 7.4 Canada Antibody Drug Conjugate Market Outlook
  • 7.5 North America Antibody Drug Conjugates Market by Technology
  • 7.6 North America Antibody Drug Conjugates Market by Payload Type
  • 7.7 North America Antibody Drug Conjugates Market by Target Antigen
  • 7.8 North America Antibody Drug Conjugates Market by Drug
  • 7.9 North America Antibody Drug Conjugates Market Analysis by Linker Type
  • 7.10 North America Antibody Drug Conjugates Market by Application

8 Europe Market Outlook (COVID Impact Recovery Analysis)

  • 8.1 How Much Worth is the Antibody Drug Conjugate Market in Europe?
  • 8.2 Europe Antibody Drug Conjugates Market by Country
  • 8.3 How Russia ADC Market is Performing?
  • 8.4 What is the Status of Germany Market?
  • 8.5 How Much Value Does UK ADC Market Holds?
  • 8.6 How Much to Expect from France ADC Market?
  • 8.7 What is the Growth Rate of Italy ADC Market?
  • 8.8 Rest of Europe ADC Market Outlook
  • 8.9 Europe Antibody Drug Conjugates Market by Technology
  • 8.10 Europe Antibody Drug Conjugates Market by Payload Type
  • 8.11 Europe Antibody Drug Conjugates Market by Target Antigen
  • 8.12 Europe Antibody Drug Conjugates Market by Drug
  • 8.13 Europe Antibody Drug Conjugates Market by Linker Type
  • 8.14 Europe Antibody Drug Conjugates Market by Application

9 Asia-Pacific Market Outlook (COVID Impact Recovery Analysis)

  • 9.1 How Big is the Asia-Pacific Market in Terms of Value?
  • 9.2 Is Japan Really Leading the Antibody Drug Conjugate Market in the Region?
  • 9.3 Why Japan is Holding Strong Position in the Region?
  • 9.4 How Big is the China ADC Market?
  • 9.5 Why ADC Market in India is Growing at Faster Rate?
  • 9.6 How South Korea Market is Performing?
  • 9.7 Is Australia ADC Market Worth Investing?
  • 9.8 Rest of Asia-Pacific ACD Market Outlook
  • 9.9 Asia-Pacific Antibody Drug Conjugates Market by Technology
  • 9.10 Asia-Pacific Antibody Drug Conjugates Market by Payload Type
  • 9.11 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen
  • 9.12 Asia-Pacific Antibody Drug Conjugates Market by Drug
  • 9.13 Asia-Pacific Antibody Drug Conjugates Market by Linker Type
  • 9.14 Asia-Pacific Antibody Drug Conjugates Market by Application

10 LAMEA Market Outlook (COVID Impact Recovery Analysis)

  • 10.1 What is the Status of Antibody Drug Conjugate Market in the Region?
  • 10.2 LAMEA Antibody Drug Conjugates Market by Country
  • 10.3 Is Brazil Leading ADC Market in the LAMEA Region?
  • 10.4 How Much Worth is Saudi Arabia ADC Market?
  • 10.5 Are there Any Opportunities in the South Africa ADC Market?
  • 10.6 How Mexico ADC Market is Performing?
  • 10.7 UAE ADC Market Outlook
  • 10.8 Rest of LAMEA Market Outlook
  • 10.9 LAMEA Antibody Drug Conjugates Market by Technology
  • 10.10 LAMEA Antibody Drug Conjugates Market by Payload Type
  • 10.11 LAMEA Antibody Drug Conjugates Market by Target Antigen
  • 10.12 LAMEA Antibody Drug Conjugates Market by Drug
  • 10.13 LAMEA Antibody Drug Conjugates Market by Linker Type
  • 10.14 LAMEA Antibody Drug Conjugates Market by Application

11 Leading Company Profiles

  • 11.1 Overview
  • 11.2 AbbVie Inc. Company
    • 11.2.1 Company Information
    • 11.2.2 Company Overview
    • 11.2.3 Company Financial Profile
    • 11.2.4 Company Product Offerings
    • 11.2.5 Company Recent Developments
  • 11.3 Astellas Pharmaceuticals Company
    • 11.3.1 Company Information
    • 11.3.2 Company Overview
    • 11.3.3 Company Financial Profile
    • 11.3.4 Company Product Offerings
    • 11.3.5 Company Recent Developments
  • 11.4 Bayer Pharmaceuticals Company
    • 11.4.1 Company Information
    • 11.4.2 Company Overview
    • 11.4.3 Company Financial Profile
    • 11.4.4 Company Product Offerings
    • 11.4.5 Company Recent Developments
  • 11.5 Celldex Therapeutics Company
    • 11.5.1 Company Information
    • 11.5.2 Company Overview
    • 11.5.3 Company Financial Profile
    • 11.5.4 Company Recent Developments
  • 11.6 Genentech Biotechnology Company
    • 11.6.1 Company Information
    • 11.6.2 Company Overview
    • 11.6.3 Company Product Offerings
    • 11.6.4 Company Recent Developments
  • 11.7 ImmunoGen Biotechnology Company
    • 11.7.1 Company Information
    • 11.7.2 Company Overview
    • 11.7.3 Company Financial Profile
    • 11.7.4 Company Recent Developments
  • 11.8 Immunomedics Inc. Company
    • 11.8.1 Company Information
    • 11.8.2 Company Overview
    • 11.8.3 Company Financial Profile
    • 11.8.4 Company Product Offerings
    • 11.8.5 Company Recent Developments
  • 11.9 Lonza Group AG Company
    • 11.9.1 Company Information
    • 11.9.2 Company Overview
    • 11.9.3 Company Financial Profile
    • 11.9.4 Company Product Offerings
    • 11.9.5 Company Recent Developments
  • 11.10 Mersana Therapeutics Inc. Company
    • 11.10.1 Company Information
    • 11.10.2 Company Overview
    • 11.10.3 Company Financial Profile
    • 11.10.4 Company Recent Developments
  • 11.11 Takeda Pharmaceuticals Company Ltd.
    • 11.11.1 Company Information
    • 11.11.2 Company Overview
    • 11.11.3 Company Financial Profile
    • 11.11.4 Company Product Offerings
    • 11.11.5 Company Recent Developments
  • 11.12 Pfizer Inc Company
    • 11.12.1 Company Information
    • 11.12.2 Company Overview
    • 11.12.3 Company Financial Profile
    • 11.12.4 Company Product Offerings
    • 11.12.5 Company Recent Developments
  • 11.13 F. Hoffmann-La Roche Ltd Company
    • 11.13.1 Company Information
    • 11.13.2 Company Overview
    • 11.13.3 Company Financial Profile
    • 11.13.4 Company Product Offerings
    • 11.13.5 Company Recent Developments
  • 11.14 Lantheus Holdings Company
    • 11.14.1 Company Information
    • 11.14.2 Company Overview
    • 11.14.3 Company Financial Profile
    • 11.14.4 Company Product Offerings
    • 11.14.5 Company Recent Developments
  • 11.15 Seattle Genetics Company
    • 11.15.1 Company Information
    • 11.15.2 Company Overview
    • 11.15.3 Company Financial Profile
    • 11.15.4 Company Product Offerings
    • 11.15.5 Company Recent Developments
  • 11.16 Merck Group Chemicals Company
    • 11.16.1 Company Information
    • 11.16.2 Company Overview
    • 11.16.3 Company Financial Profile
    • 11.16.4 Company Product Offerings
    • 11.16.5 Company Recent Developments

12 Antibody Drug Conjugate Product Pipeline Analysis

  • 12.1 Manufacturer Strategies
  • 12.2 1.Celldex Therapeutics.
  • 12.3 Synthetic Modified Vaccines
    • 12.3.1 Fully Synthetic Carbohydrate-Based Vaccines
    • 12.3.2 A Synthetic Vaccine Against Meningococcal
    • 12.3.3 Recent Development

13 Conclusion and Recommendations

  • 13.1 List of Other Key Companies in the Market
  • 13.2 List of Organizations Associated with Drugs

List of Figures

  • Figure 1.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)
  • Figure 3.1 Antibody Drug Conjugate Action Mechanism Overview
  • Figure 5.1 Global Cancer Cases Breakdown by Gender and Type, 2019
  • Figure 6.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)
  • Figure 6.2 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 6.3 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 6.4 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 6.5 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 6.6 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %)
  • Figure 6.7 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 6.8 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 6.9 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 6.10 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 6.11 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)
  • Figure 6.12 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 6.13 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 6.14 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 6.15 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 6.16 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 6.17 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 6.18 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 6.19 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 6.20 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 6.21 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 6.22 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 6.23 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 6.24 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 6.25 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 6.26 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 6.27 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 6.28 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 6.29 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 6.30 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 6.31 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 6.32 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 6.33 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 6.34 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 6.35 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 7.1 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)
  • Figure 7.2 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 7.3 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 7.4 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 7.5 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 7.6 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)
  • Figure 7.7 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 7.8 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 7.9 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 7.10 North America Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 7.11 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)
  • Figure 7.12 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 7.13 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 7.14 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 7.15 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 7.16 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 7.17 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 7.18 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 7.19 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 7.20 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 7.21 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 7.22 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 7.23 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 7.24 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 7.25 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 7.26 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 7.27 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 7.28 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 7.29 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 7.30 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 7.31 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 7.32 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 7.33 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 7.34 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 7.35 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 7.36 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)
  • Figure 7.37 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 7.38 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 7.39 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 7.40 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 8.1 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)
  • Figure 8.2 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 8.3 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 8.4 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 8.5 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 8.6 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)
  • Figure 8.7 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 8.8 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 8.9 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 8.10 Europe Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 8.11 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)
  • Figure 8.12 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 8.13 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 8.14 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 8.15 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 8.16 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 8.17 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 8.18 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 8.19 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 8.20 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 8.21 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 8.22 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 8.23 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 8.24 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 8.25 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 8.26 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 8.27 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 8.28 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 8.29 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 8.30 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 8.31 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 8.32 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 8.33 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 8.34 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 8.35 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 8.36 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)
  • Figure 8.37 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 8.38 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 8.39 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 8.40 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 9.1 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)
  • Figure 9.2 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 9.3 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 9.4 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 9.5 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 9.6 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)
  • Figure 9.7 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 9.8 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 9.9 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 9.10 Asia-Pacific Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 9.11 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)
  • Figure 9.12 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 9.13 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 9.14 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 9.15 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 9.16 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 9.17 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 9.18 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 9.19 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 9.20 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 9.21 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 9.22 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 9.23 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 9.24 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 9.25 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 9.26 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 9.27 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 9.28 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 9.29 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 9.30 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 9.31 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 9.32 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 9.33 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 9.34 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 9.35 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 9.36 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)
  • Figure 9.37 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 9.38 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 9.39 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 9.40 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 10.1 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %)
  • Figure 10.2 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 10.3 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 10.4 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 10.5 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 10.6 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %)
  • Figure 10.7 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 10.8 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 10.9 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 10.10 LAMEA Antibody Drug Conjugates Market by Country Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 10.11 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %)
  • Figure 10.12 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 10.13 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 10.14 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 10.15 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 10.16 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 10.17 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 10.18 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 10.19 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 10.20 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 10.21 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 10.22 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 10.23 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 10.24 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 10.25 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 10.26 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 10.27 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 10.28 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 10.29 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 10.30 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 10.31 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %)
  • Figure 10.32 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (V-Shape Recovery)
  • Figure 10.33 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (W-Shape Recovery)
  • Figure 10.34 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (U-Shape Recovery)
  • Figure 10.35 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %) (L-Shape Recovery)
  • Figure 10.36 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %)
  • Figure 10.37 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (V-Shaped Recovery)
  • Figure 10.38 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (W-Shaped Recovery)
  • Figure 10.39 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (U-Shaped Recovery)
  • Figure 10.40 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %) (L-Shaped Recovery)
  • Figure 11.1 AbbVie Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.2 AbbVie Inc: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.3 AbbVie Inc: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.4 AbbVie Inc: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.5 Astellas Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.6 Astellas Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.7 Astellas Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.8 Astellas Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.9 Bayer Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.10 Bayer Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.11 Bayer Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.12 Bayer Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.13 Celldex Therapeutics: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.14 Celldex Therapeutics: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.15 Celldex Therapeutics: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.16 Celldex Therapeutics: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.17 ImmunoGen Biotechnology: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.18 ImmunoGen Biotechnology: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.19 ImmunoGen Biotechnology: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.20 ImmunoGen Biotechnology: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.21 Immunomedics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.22 Immunomedics Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.23 Immunomedics Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.24 Immunomedics Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.25 Lonza Group AG: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.26 Lonza Group AG.: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.27 Lonza Group AG.: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.28 Lonza Group AG.: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.29 Mersana Therapeutics Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.30 Mersana Therapeutics Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.31 Mersana Therapeutics Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.32 Mersana Therapeutics Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.33 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.34 Takeda Pharmaceuticals: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.35 Takeda Pharmaceuticals: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.36 Takeda Pharmaceuticals: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.37 Pfizer Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.38 Pfizer Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.39 Pfizer Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.40 Pfizer Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.41 La Roche Ltd. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.42 La Roche Ltd. Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.43 La Roche Ltd. Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.44 La Roche Ltd. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.45 Lantheus Holdings Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.46 Lantheus Holdings Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.47 Lantheus Holdings Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.48 Lantheus Holdings Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.49 Seattle Genetics Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.50 Seattle Genetics Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.51 Seattle Genetics Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.52 Seattle Genetics Company: Company Net Income/Loss 2015-2019 (US$ Mn)
  • Figure 11.53 Merck Group Chemicals Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Figure 11.54 Merck Group Chemicals Company: Company Operating Income 2015-2019 (US$ Mn)
  • Figure 11.55 Merck Group Chemicals Company: Company EBITDA 2015-2019 (US$ Mn)
  • Figure 11.56 Merck Group Chemicals Company: Company Net Income/Loss 2015-2019 (US$ Mn)

List of Tables

  • Table 1.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 2.1 Global Antibody Drug Conjugate Market Summary
  • Table 2.2 Global Antibody Drug Conjugate Market by Drugs and FDA Approval Details
  • Table 3.1 Types of Antibody Drug Conjugates Based on Type of Monoclonal Antibody
  • Table 4.1 Global Antibody Drug Conjugate Market by Drugs and FDA Approval Details
  • Table 4.2 60 ADC Projects Under Development In The Global Market
  • Table 5.1 Number of Cancer Cases in 2019
  • Table 6.1 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 6.2 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 6.3 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 6.4 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 6.5 Global Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 6.6 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 6.7 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 6.8 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 6.9 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 6.10 Global Antibody Drug Conjugates Market by Region Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 6.11 Significant Antibody Drug Conjugate Linkers
  • Table 6.12 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 6.13 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 6.14 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 6.15 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 6.16 Global Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 6.17 Significant Antibody Drug Conjugate Payloads
  • Table 6.18 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 6.19 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 6.20 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 6.21 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 6.22 Global Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 6.23 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 6.24 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 6.25 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 6.26 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 6.27 Global Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 6.28 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 6.29 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 6.30 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 6.31 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 6.32 Global Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 6.33 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 6.34 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 6.35 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 6.36 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 6.37 Global Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 7.1 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 7.2 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 7.3 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 7.4 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 7.5 North America Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 7.6 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 7.7 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 7.8 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 7.9 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 7.10 US Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 7.11 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US$bilion, AGR %, CAGR %)
  • Table 7.12 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 7.13 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 7.14 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 7.15 Canada Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 7.16 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 7.17 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 7.18 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 7.19 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 7.20 North America Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 7.21 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 7.22 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 7.23 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 7.24 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 7.25 North America Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 7.26 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 7.27 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 7.28 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 7.29 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 7.30 North America Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 7.31 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 7.32 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 7.33 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 7.34 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 7.35 North America Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 7.36 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 7.37 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 7.38 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 7.39 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 7.40 North America Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 7.41 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 7.42 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 7.43 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 7.44 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 7.45 North America Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.1 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.2 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.3 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.4 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.5 Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.6 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.7 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.8 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.9 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.10 Russia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.11 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.12 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.13 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.14 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.15 Germany Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.16 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.17 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.18 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.19 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.20 UK Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.21 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.22 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.23 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.24 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.25 France Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.26 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.27 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.28 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.29 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.30 Italy Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.31 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.32 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.33 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.34 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.35 Rest of Europe Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.36 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.37 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.38 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.39 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.40 Europe Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 8.41 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 8.42 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 8.43 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 8.44 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 8.45 Europe Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 8.46 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 8.47 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 8.48 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 8.49 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 8.50 Europe Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 8.51 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 8.52 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 8.53 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 8.54 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 8.55 Europe Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 8.56 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 8.57 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 8.58 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 8.59 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 8.60 Europe Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 8.61 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 8.62 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 8.63 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 8.64 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 8.65 Europe Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.1 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.2 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.3 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.4 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.5 Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.6 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.7 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.8 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.9 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.10 Japan Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.11 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.12 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.13 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.14 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.15 China Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.16 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.17 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.18 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.19 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.20 India Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.21 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.22 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.23 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.24 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.25 South Korea Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.26 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.27 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.28 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.29 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.30 Australia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.31 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.32 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.33 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.34 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.35 Rest of Asia-Pacific Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.36 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.37 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.38 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.39 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.40 Asia-Pacific Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 9.41 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 9.42 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 9.43 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 9.44 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 9.45 Asia-Pacific Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 9.46 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 9.47 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 9.48 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 9.49 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 9.50 Asia-Pacific Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 9.51 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 9.52 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 9.53 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 9.54 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 9.55 Asia-Pacific Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 9.56 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 9.57 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 9.58 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 9.59 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 9.60 Asia-Pacific Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 9.61 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 9.62 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 9.63 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 9.64 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 9.65 Asia-Pacific Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.1 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.2 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.3 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.4 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.5 LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.6 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.7 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.8 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.9 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.10 Brazil Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.11 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.12 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.13 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.14 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.15 Saudi Arabia Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.16 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.17 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.18 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.19 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.20 South Africa Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.21 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.22 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.23 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.24 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.25 Mexico Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.26 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.27 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.28 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.29 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.30 UAE Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.31 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.32 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.33 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.34 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.35 Rest of LAMEA Antibody Drug Conjugates Market by Value Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.36 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.37 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.38 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.39 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.40 LAMEA Antibody Drug Conjugates Market by Technology Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 10.41 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 10.42 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 10.43 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 10.44 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 10.45 LAMEA Antibody Drug Conjugates Market by Payload Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 10.46 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 10.47 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 10.48 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 10.49 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 10.50 LAMEA Antibody Drug Conjugates Market by Target Antigen Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 10.51 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 10.52 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 10.53 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 10.54 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 10.55 LAMEA Antibody Drug Conjugates Market by Drug Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 10.56 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %)
  • Table 10.57 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (V-Shape Recovery)
  • Table 10.58 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (W-Shape Recovery)
  • Table 10.59 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (U-Shape Recovery)
  • Table 10.60 LAMEA Antibody Drug Conjugates Market by Linker Type Forecast 2021-2031 (US$ billion, AGR %, CAGR %) (L-Shape Recovery)
  • Table 10.61 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %)
  • Table 10.62 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (V-Shaped Recovery)
  • Table 10.63 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (W-Shaped Recovery)
  • Table 10.64 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (U-Shaped Recovery)
  • Table 10.65 LAMEA Antibody Drug Conjugates Market by Application Forecast 2021-2031 (US $billion, AGR %, CAGR %) (L-Shaped Recovery)
  • Table 11.1 AbbVie Inc: Company Information
  • Table 11.2 AbbVie Inc: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.3 AbbVie Inc: Company Product and Service Offerings
  • Table 11.4 AbbVie Inc: Company Recent Developments till Sept,2020
  • Table 11.5 Astellas Pharmaceuticals: Company Information
  • Table 11.6 Astellas Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.7 Astellas Pharmaceuticals: Company Product and Service Offerings
  • Table 11.8 Astellas Pharmaceuticals: Company Recent Developments till Sept,2020
  • Table 11.9 Bayer Pharmaceuticals: Company Information
  • Table 11.10 Bayer Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.11 Bayer Pharmaceuticals: Company Product and Service Offerings
  • Table 11.12 Bayer Pharmaceuticals: Company Recent Developments till Sept,2020
  • Table 11.13 Celldex Therapeutics: Company Information
  • Table 11.14 Celldex Therapeutics: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.15 Celldex Therapeutics: Company Recent Developments till Sept,2020
  • Table 11.16 Genentech Biotechnology: Company Information
  • Table 11.17 Genentech Biotechnology: Company Product and Service Offerings
  • Table 11.18 Genentech Biotechnology: Company Recent Developments till Sept,2020
  • Table 11.19 ImmunoGen Biotechnology: Company Information
  • Table 11.20 ImmunoGen Biotechnology. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.21 ImmunoGen Biotechnology: Company Recent Developments till Sept,2020
  • Table 11.22 Immunomedics Inc: Company Information
  • Table 11.23 Immunomedics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.24 Immunomedics Inc: Company Product and Service Offerings
  • Table 11.25 Immunomedics Inc: Company Recent Developments till Sept,2020
  • Table 11.26 Lonza Group AG: Company Information
  • Table 11.27 Lonza Group AG.: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.28 Lonza Group AG: Company Product and Service Offerings
  • Table 11.29 Lonza Group AG: Company Recent Developments till Sept,2020
  • Table 11.30 Mersana Therapeutics Inc: Company Information
  • Table 11.31 Mersana Therapeutics Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.32 Mersana Therapeutics Inc: Company Recent Developments till Sept,2020
  • Table 11.33 Takeda Pharmaceuticals: Company Information
  • Table 11.34 Takeda Pharmaceuticals: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.35 Takeda Pharmaceuticals: Company Product and Service Offerings
  • Table 11.36 Takeda Pharmaceuticals: Company Recent Developments till Sept,2020
  • Table 11.37 Pfizer Inc: Company Information
  • Table 11.38 Pfizer Inc. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.39 Pfizer Inc: Company Product and Service Offerings
  • Table 11.40 Pfizer Inc: Company Recent Developments till Sept,2020
  • Table 11.41 La Roche Ltd: Company Information
  • Table 11.42 La Roche Ltd. Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.43 La Roche Ltd: Company Product and Service Offerings
  • Table 11.44 La Roche Ltd: Company Recent Developments till Sept,2020
  • Table 11.45 Lantheus Holdings: Company Information
  • Table 11.46 Lantheus Holdings Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.47 Lantheus Holdings: Company Product and Service Offerings
  • Table 11.48 Lantheus Holdings: Company Recent Developments till Sept,2020
  • Table 11.49 Seattle Genetics: Company Information
  • Table 11.50 Seattle Genetics Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.51 Seattle Genetics: Company Product and Service Offerings
  • Table 11.52 Seattle Genetics: Company Recent Developments till Sept,2020
  • Table 11.53 Merck Group Chemicals: Company Information
  • Table 11.54 Merck Group Chemicals Company: Company Revenue 2015-2019 (US$ Mn, AGR %)
  • Table 11.55 Merck Group Chemicals: Company Product and Service Offerings
  • Table 11.56 Merck Group Chemical: Company Recent Developments till Sept,2020
  • Table 12.1 AbbVie Inc: Company Product Pipeline
  • Table 12.2 Astellas Pharmaceutics: Company Product Pipeline
  • Table 12.3 Bayer Pharmaceutics: Company Product Pipeline
  • Table 12.4 Celldex Therapeutics: Company Product Pipeline
  • Table 12.5 Genentech Biotechnology: Company Product Pipeline
  • Table 12.6 ImmunoGen Biotechnology: Company Product Pipeline
  • Table 12.7 Immunomedics Inc: Company Product Pipeline
  • Table 12.8 Mersana Therapeutics: Company Product Pipeline
  • Table 12.9 Takeda Pharmaceuticals: Company Product Pipeline
  • Table 12.10 Pfizer Inc: Company Product Pipeline
  • Table 12.11 Roche Ltd: Company Product Pipeline
  • Table 12.12 Lantheus Holdings: Company Product Pipeline
  • Table 12.13 Seattle Genetics: Company Product Pipeline
  • Table 12.14 Merck Group Chemicals: Company Product Pipeline

List of Companies Profiled in the report:

  • AbbVie Inc.
  • Astellas Pharma Inc
  • Bayer Pharmaceuticals
  • Celldex Therapeutics, Inc.
  • Genentech Biotechnology
  • ImmunoGen Biotechnology
  • Immunomedics Inc
  • Lantheus Holdings, Inc.
  • Lonza Group AG (Lonza)
  • Merck KGaA
  • Mersana Therapeutics Inc.
  • Pfizer Inc. (Pfizer)
  • Roche Holding AG (Roche)
  • Seattle Genetics, Inc.
  • Takeda Pharmaceutical Company Limited

List of Other Companies Mentioned in the report:

  • Abgenomics International Inc
  • Abzena Plc
  • ADC Bio
  • Adc Biotechnology Ltd.
  • Adc Therapeutics Sa
  • Affinicon Aps
  • Agensys Inc.
  • Agensys, Inc.
  • Ambrx Inc.
  • Amgen Inc.
  • Antikor
  • Antikor Biopharma Ltd.
  • Astellas Pharma U.S. Inc.
  • Astrazeneca Plc
  • Bayer Ag
  • Bionavigen
  • Bioss Antibodies
  • Biotecnol
  • Biotest Ag
  • Biotest Pharmaceuticals
  • Bristol Myers Squibb
  • Bristol-Myers Squibb Co.
  • Catalent Pharma Solutions
  • Celldex Therapeutics Inc
  • Celltrion
  • Centrose
  • Concortis Biotherapeutics
  • Creative Biolabs
  • Cytomx Therapeutics Inc
  • Daiichi Sankyo Co. Ltd
  • Dalton Pharma Services
  • Eli Lilly And Co
  • Esperance Pharmaceuticals Inc.
  • F. Hoffmann-La-Roche Ag (Roche)
  • Formation Biologics
  • Genmab A/S
  • Glaxosmithkline Plc
  • Heidelberg Pharma
  • Heidelberg Pharma Gmbh
  • Immunogen Inc.
  • Immunomedics Inc.
  • Lonza Pharma & Biotech
  • MabPlex
  • Mersana Therapeutics
  • Mersana Therapeutics Inc
  • Millennium Pharmaceuticals
  • Millennium Pharmaceuticals Inc. (Now Takeda Oncology)
  • MilliporeSigma
  • Minakem High Potent
  • Morphosys Ag
  • Nbe Therapeutics
  • Oxford Biotherapeutics
  • Pfizer Inc.
  • Philogen Spa
  • Pierre Fabre
  • Progenics Pharmaceuticals Inc.
  • Seattle Genetics Inc.
  • Sevion Therapeutics
  • Sorrento Therapeutics Inc
  • Sutro Biopharma Inc.
  • Synthon
  • Synthon Bv
  • Viventia Biotechnologies Inc.
  • Zhejiang Medicine Co. Ltd.

List of Associations:

  • Australian Therapeutic Goods Administration (TGA)
  • Canadian International Pharmacy Association
  • Central Drugs Standard Control Organization (CDSCO) of India
  • China's National Medical Products Administration (NMPA)
  • Contract Development and Manufacturing Organization (CDMO)
  • Drug Enforcement Administration (DEA)
  • Drug Information Association
  • International Confederation of Alcohol, Tobacco and other Drug (ATOD) Research Associations
  • International Conference of Drug Regulatory Authorities
  • International Drug Abuse Research Society (IDARS)
  • International Generic and Biosimilar medicines Association (IGBA)
  • International Narcotics Control Board (INCB)
  • International Narcotics Interdiction Association: INIA
  • International Society for Pharmaceutical Engineering
  • International Society of Drug Bulletins ISDB
  • Investigational New Drug application (IND)
  • Parenteral Drug Association
  • The International Dispensary Association Foundation
  • The International Drug Policy Consortium (IDPC)
  • The International Society for the Study of Drug Policy (ISSDP)
  • United States Food and Drug Administration (FDA)